Cargando…
Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing’s sarcoma via inhibition of cell migration
BACKGROUND: Ewing’s sarcoma (ES) is the second most frequent primitive malignant bone tumor in adolescents with a very poor prognosis for high risk patients, mainly when lung metastases are detected (overall survival <15% at 5 years). Zoledronic acid (ZA) is a potent inhibitor of bone resorption...
Autores principales: | Odri, Guillaume, Kim, Pui-Pui, Lamoureux, François, Charrier, Céline, Battaglia, Séverine, Amiaud, Jérôme, Heymann, Dominique, Gouin, François, Redini, Françoise |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975287/ https://www.ncbi.nlm.nih.gov/pubmed/24612486 http://dx.doi.org/10.1186/1471-2407-14-169 |
Ejemplares similares
-
Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL
por: Picarda, Gaëlle, et al.
Publicado: (2013) -
Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1
por: Jacques, Camille, et al.
Publicado: (2016) -
Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma
por: Lamoureux, Francois, et al.
Publicado: (2014) -
Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma
por: Redini, Françoise, et al.
Publicado: (2015) -
Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases
por: Lamora, Audrey, et al.
Publicado: (2015)